Although our analysis requires a large-scale validation, it suggests a potential mechanism-based selection strategy, in which patients with a higher expression of IL-1β in BC tissue may have a better immune response and probably a better response to cancer treatments. The gene discussed is IL1B; the disease is breast cancer.